This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Abstract Background: Low concentration C-reactive protein (CRP) has favorable prognostic significance in patients with cardiovascular risks. Methods: We compared the wr-CRP method with the hs-CRP method both on Roche Cobas c702 analyzer for the determination of low CRP concentration (<20 mg/L) including 200 patients treated in Cardiology Department in Beijing Tsinghua Changgung Hospital (Beijing, China) Results: The two methods were highly correlated (Spearman's rho = 0.995). Deming regression was used to fit the regression analysis model, giving a slope of 1.058
| INTRODUC TI ON
In terms of clinical application, CRP seems to be a stronger predictor for early detection of asymptomatic individuals at risk for future vascular events. 1, 2 Using widely available high-sensitivity assays, CRP levels of <1, 1-3, and >3 mg/L correspond to low-, moderate-, and high-risk groups for future cardiovascular events. [3] [4] [5] It has been shown that individuals with a CRP level of >3 mg/L have an adjusted 10-year relative risk of 1.45 of coronary heart disease compared to individuals with <1 mg/L 3 .
Ideally, physicians order one single test and obtain either a low CRP result predicting low atherosclerotic risk or a high CRP result indicating rather severe inflammation. This option might minimize confusion in ordering laboratory tests and decrease the patients' medical expenditure. 6, 7 Nephelometry and immunoturbidimetry techniques have been developed to determine serum CRP in low concentration. 8, 9 Over the last several years, wide-range C-reactive protein (wr-CRP) has been proposed as an alternative to high-sensitivity C-reactive protein (hs-CRP) in microinflammation detection and cardiovascular risk assessment. Ori Rogowski, et al 10 shown that Roche Cobas c501 wr-CRP has been proposed as an economical alternative to Roche Modular P800 hs-CRP for the evaluation of low-grade inflammation-associated cardiovascular risk. The Roche wr-CRP assay with a similar limit of quantitation is more use expedient with wider detecting linearity and lower costs.
The objective of this study was to assess the concordance of wr-CRP and hs-CRP methods in the determination of low concentration of C-reactive protein in patients with cardiovascular risk and verify results from these studies.
| MATERIAL S AND ME THODS

| Samples
We enrolled patients with low CRP concentration with atherothrombosis risk treated in the Cardiology Department of Beijing Tsinghua Changgung Hospital from December 2018 to March 2019 in which either wr-CRP or hs-CRP was assayed, and excluded those with CRP ≥ 20 mg/L. Each participant was enrolled once and 200 cases met our criteria. Blood samples were collected in heparin-lithium anticoagulated tubes (Vacuette Greiner, ref#474084) and analyzed within 4 hours after blood is withdrawn. All tubes were centrifuged on Sorvall ST 16R centrifuge (Thermo Scientific) for 10 min at 2000 g (temperature 19.0 ± 0.4°C). were used for statistical analysis.
| Assay procedures
| RE SULTS
We enrolled 200 participants with CRP level of <20 mg/L assayed with either wr-CRP or hs-CRP method in the study. The mean ± SD age of participants was 46.3 ± 6.7 years (84 women and 116 men, respective mean ± SD age being 46.7 ± 6.4 and 46.1 ± 7.0 years).
Between-run precision (six consecutive months) showed coefficients of variation in the range of 2.78%-4.24% and 2.72%-4.51% for the wr-CRP and hs-CRP methods, respectively. The median of CRP results by wr-CRP method (2.800 mg/L) was significantly higher than that of hs-CRP method (2.680 mg/L; Z = −6.901, P < 0.001).
| Correlation and regression
C-reactive protein results were not normally distributed, so Spearman's rank correlation analysis was used to assess correlations between both methods. As shown in Table 1 , the CRP results showed a significant correlation between both methods for 
| Method comparison and bias evaluation
Ranked order difference plots and ranked order percent difference plots between both methods were drawn referring to the CLSI EP09C protocol. The differences exhibited a constant coefficient of variation. The median method difference (wr-CRP − hr-CRP) was 0.120 mg/L (95% CI, 0.086-0.200 mg/L; Figure 2A ), and the median percent difference [(wr-CRP − hr-CRP)/hr-CRP × 100%] was 7.34% (95% CI, 4.27%-8.47%; Figure 2B ). Besides, the predicted bias was calculated using the equation from the Deming regression analysis. The percent bias between both methods at the given cutoff CRP values of 1, 3, and 10 mg/L evaluated by Deming regression analysis was 6.60%, 6.07%, and 5.88%, respectively. In addition, the percent biases evaluated by Passing-Bablok regression and ordinary linear regression were all less than the acceptable standard (12.50%; Table 2 ).
| Agreement assessment
We further assessed the agreement between both methods by kappa statistic. The percentages of low-, moderate-, and high-risk TA B L E 1 Spearman's rank correlation and Deming regression of CRP results between wr-CRP and hs-CRP methods 
| D ISCUSS I ON
This study confirms that wr-CRP immunoturbidimetry assay is highly Prevention (CDC) and the American Heart Association (AHA). 16 The slope and intercept were not significantly different from 1 and 0 in low-and moderate-risk groups. The 95% CI of slope in high-risk group was 1.046-1.246, not including 1. It may be considered that there was a small proportional deviation between wr-CRP and hs-CRP in high-risk group. Considering that the different regression models may affect the results of bias evaluation, the percent bias was further evaluated by three regression models between both methods at the given cutoff CRP values of 1, 3, and 10 mg/L, and all the percent bias were acceptable in clinical practice. Agreement study showed that the classification concordance rate was 96.0%, indicating almost perfect agreement between both methods. The reclassification rate was 4.0%, mainly over-estimation of the risk using the Roche wr-CRP method.
The currently used tertile cut points are derived from Caucasian population, 16 which may not be appropriate for Asian population groups.
Further research is needed to determine the utility of hs-CRP measurements for cardiovascular risk prediction in Asian populations, and the appropriate cut point values derived from these populations are needed. 13 Moreover, additional clinical and biological data such as hypersensitive troponin are required for further study.
Overall, this study is close to those of previous studies, which showed a strong correlation between wr-CRP and hs-CRP at low concentrations <20 mg/L. In view of its advantages of convenience and low costs, the Roche wr-CRP assay may be used as an alternative to Roche hs-CRP method for routine evaluation of the cardiovascular risk for patients with low concentration of CRP. The authors declare that they have no conflict of interest.
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